Two news items today show the relevance of CYGX technology.
The first is yet another antisense drug making headlines. RNA based medicine - of which we are a unique part - is getting hotter by the day.
The second underscores the seriousness of resistant bacterial infections. We have applied for a patent for a whole new class of ssDNA based antibiotics that will defeat bacteria at a level too basic for them to mutate around.
We are sitting soooo pretty. IMO
AVI drug reduces restenosis
Shares of AVI BioPharma rose 8 percent after the company presented data showing the antisense drug Resten-NG was safe and reduced restenosis following angioplasty surgery. The Phase II study enrolled 57 people undergoing angioplasty. Patients received placebo, a 3 mg subtherapeutic dose, or 10 mg therapeutic dose of Resten-NG. The primary endpoint was angiographic analysis after six months. Roughly one-third of patients in the placebo and subtherapeutic arms of the study showed signs of restenosis after six months compared with 8.3 percent of those receiving a therapeutic dose of Resten-NG. The results were presented at the Transcatheter Cardiovascular Therapeutics meeting in Washington.
Staph infections cost $24,034 per episode
Two studies conducted by Duke University Medical Center found the mean cost of treating Staph aureus in patients with end-stage renal disease was $24,034 per episode. The study analyzed 210 hemodialysis-dependent patients treated at Duke University Hospital. The total cost of treatment included initial treatment expenses, readmissions, and outpatient costs. The pharmacoeconomic data was presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy in Chicago. The studies were sponsored by Nabi Biopharmaceuticals.
AI
Market Data 
Markets 
